Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · 2 days ago
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)GlobeNewsWire · Sep 29, 2026
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 17, 2026
Dyne Therapeutics, Inc. (DYN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 ClassSeeking Alpha · Sep 9, 2026
Stock Traders Buy High Volume of Dyne Therapeutics Call Options (NASDAQ:DYN)Defense World · Sep 9, 2026Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.75 | -$1.08 | Miss |
| May 11, 2026 | -$0.77 | -$0.73 | Beat |
| Mar 2, 2026 | -$0.74 | -$0.76 | Miss |
| Nov 5, 2025 | -$0.81 | -$0.76 | Beat |
| Jul 28, 2025 | -$0.99 | -$0.97 | Beat |
| May 8, 2025 | -$0.88 | -$1.05 | Miss |